Compare
Tempest Therapeutics, Inc. vs Lipocine Inc. vs Impact Biomedical Inc. vs Cerenome, Inc.
| Latest fiscal year | Tempest Therapeutics, Inc. TPST | Lipocine Inc. LPCN | Impact Biomedical Inc. IBO | Cerenome, Inc. CNSY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.98M | $32.0K | $5.21M |
| Revenue growth (YoY) | n/a | -82.3% | n/a | -10.5% |
| Gross margin | n/a | n/a | n/m (computed) | n/a |
| Operating margin | n/a | -524.7% | n/m | -293.5% |
| Net margin | n/a | -487.1% | n/m | -429.4% |
| Net income | -$26.26M | -$9.63M | -$11.84M | -$22.39M |
| EPS (Diluted) | -$6.33 | -$1.69 | -$0.38 | -$0.29 |
| Operating cash flow | -$26.82M | -$9.76M | -$1.89M | -$20.77M |
| Free cash flow | -$26.82M | n/a | n/a | -$20.84M |
| Cash & equivalents | $7.71M | $5.21M | $3.0K | $4.26M |
| Total assets | $16.93M | $17.01M | $17.41M | $16.32M |
| Total liabilities | $10.26M | $2.53M | $1.85M | $12.33M |
| Shareholders' equity | $6.67M | $14.48M | $12.61M | $4.00M |
| Return on year-end equity | -393.9% | -66.5% | -93.9% | -560.2% |
| Shares outstanding | 4.93M | 6.16M | 104.62M | 138.68M |
Revenue, most recent five fiscal years
| Fiscal year | Tempest Therapeutics, Inc. | Lipocine Inc. | Impact Biomedical Inc. | Cerenome, Inc. |
|---|---|---|---|---|
| Latest | $295.0K Ended 2017-12-31 | $1.98M Ended 2025-12-31 | $32.0K Ended 2025-12-31 | $5.21M Ended 2025-12-31 |
| 1 year earlier | $653.0K Ended 2016-12-31 | $11.20M Ended 2024-12-31 | n/a | $5.82M Ended 2024-12-31 |
| 2 years earlier | $277.0K Ended 2015-12-31 | -$2.85M Ended 2023-12-31 | n/a | $4.91M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2014-12-31 | $500.0K Ended 2022-12-31 | $50.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $0 Ended 2013-12-31 | $16.14M Ended 2021-12-31 | n/a | n/a |